Addiction Medicine Updates
Latest News & Upcoming Events
A recent headline highlighting New Jersey as the first state to authorize paramedics to start addiction treatment at the scene of an overdose, prompted Open Minds Director of Market Intelligence, Athena Mandros, to explore the concept further. In her article, she...
About one in five Canadian adolescents uses cannabis. Neuroscientists have been researching the effects of cannabis on the adolescent brain. Adolescence is associated with the maturation of cognitive functions, such as working memory, decision-making, impulsivity...
Louis Trevisan, M.D. has been named the new CSAT director at SAMHSA. Dr. Trevisan is a board-certified Addiction Psychiatrist with extensive experience in substance use and mental disorders treatment with a special focus on the older adult population. Prior to joining...
Opioid dependence is epidemic in the United States. While progress has been made in training providers, the gap in providing effective treatment of opioid use disorders continues to widen, moving beyond heroin addicted individuals to a much larger and diverse segment of the population. This increase is predominantly due to an alarming increase in addiction to prescription opioid analgesic medications. Buprenorphine, the most recent addition to the pharmacotherapies available to treat opioid dependence, is novel among the opioid pharmacotherapies because of its partial agonist properties. It has been placed on Schedule III and is available by prescription from a physician’s office-based practice.
Recognizing the impact of this addiction, as well as learning how to treat opioid use disorders, are important steps in combating this ever growing medical problem. To obtain the waiver to prescribe, providers are required to take specialized training. PCSS-MAT uses the Half-and-Half format (first, 4.25 hours of face-to-face training with an instructor, followed by 3.75 hours of on-your-own-training that must be completed along with a post test). This training meets the requirements for physicians; however additional training is required for advanced practice providers. The training focuses on specifics of treating patients with opioid use disorders in office-based settings and clinical vignettes to help trainees think through “real life” experiences in opioid use disorders treatment. Once the waiver training is completed in full, participants will receive a CME certificate of attendance from AAAP.
This program includes up to 2.0 hours of controlled substances content. Per NCAC rules: As of July 1, 2017, all physicians (other than residents), physician assistants, nurse practitioners, podiatrists, and dentists who prescribe controlled substances must satisfy the controlled-substance prescribing CE requirements as set forth by their licensing boards. Requirements vary by discipline and board.
The program is recommended for prescribers in primary care, emergency medicine, pain management, psychiatric, HIV, and addiction medicine. (Not a prescriber? CLICK HERE)
- Review addiction treatment in office-based practices
- Discuss the pharmacological treatments of opioid use disorder
- Determine what medical record documentation must be followed
- Discuss the process of buprenorphine induction as well as stabilization and maintenance techniques
- Describe how to take a patient history and evaluation
- Review safety concerns and drug interactions
Opioid addiction is a chronic, relapsing brain disease that affects millions of Americans and produces a tremendous burden on the healthcare system. In 2002, U.S. physicians gained the opportunity to treat opioid-addicted patients with buprenorphine in primary care settings, commonly referred to as office-based opioid treatment (OBOT). OBOT has been shown to be effective in primary care settings and impacts public health through the reduction of opioid use, opioid overdose mortality and transmission of infectious diseases. However, it remains underutilized.
One consistently cited barrier preventing OBOT expansion is lack of adequate clinical support given the additional needs for patient monitoring. Successful medication-assisted treatment (MAT) requires a team-based approach just like treatment for other chronic diseases. In addition, treatment is more effective when providers can use a trauma-informed and gender-responsive treatment plan.
The goal of this companion program to the AAAP Clinical Support System: Buprenorphine Office-Based Treatment for Opioid Use Disorders (The “Half and Half” Course) is to increase the comfort level and expertise of the healthcare team by outlining a team approach, trauma-informed interventions, gender-responsive care, and recommendations for implementation of buprenorphine OBOT.
Nurses, mental health professionals including substance abuse counselors, social workers, psychologists, marriage and family therapists, school counselors, practice managers, program administrators, medical assistants, care managers and coordinators and other professionals interested in this subject.
- Describe the presented framework of office-based opioid treatment (OBOT) including practice changes, medications used, psychosocial services and integration/coordination components
- Utilize evidence-based interventions that are trauma-informed and gender-responsive to treat persons with substance use disorders
- Define the roles of an effective practice team, including primary care and behavioral health clinicians, working together with patients and families, and using a systematic and cost-effective approach to provide patient-centered care for opioid and other substance use disorders
- Increase medical and behavioral health professionals’ receptivity and capability to work collaboratively as they evaluate and manage opioid and other substance use disorders using SBIRT (screening, brief intervention and referral to treatment)
- List key components of evidence-based and effective OBOT